Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851995 | 0.80 | — | — | |
| SCHEMBL6796489 | 0.77 | OPRD1 (0.47) | OPRD1MAPTSIGMAR1KDM4ECYP1A2 | |
| SCHEMBL18661822 | 0.77 | OPRD1 (0.47) | OPRD1MAPTSIGMAR1KDM4ECYP1A2 | |
| SCHEMBL23867088 | 0.69 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL6927881 | 0.68 | OPRD1 (0.61) | OPRD1MAPTSIGMAR1KDM4ECYP1A2 | |
| SCHEMBL10664305 | 0.67 | SIGMAR1 (0.47) | MAPTSIGMAR1 | |
| Hydrochloric Acid SCHEMBL27678019 | 0.67 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL13993922 | 0.67 | MAPT (0.43) | OPRD1MAPTKDM4ECYP1A2CYP3A4 | |
| SCHEMBL4598452 | 0.67 | OPRD1 (0.46) | OPRD1MAPTKDM4ECYP1A2CYP3A4 | |
| SCHEMBL4598449 | 0.67 | OPRD1 (0.46) | OPRD1MAPTKDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | MCHR1, MCHR2, MC4R | OPRD1 49/4885MAPT 3254/4885SIGMAR1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.